Display options
Share it on

Gels. 2021 Apr 28;7(2). doi: 10.3390/gels7020051.

Effect of Doxycycline Microencapsulation on Buccal Films: Stability, Mucoadhesion and In Vitro Drug Release.

Gels (Basel, Switzerland)

Venu Gopal Reddy Patlolla, Nikolina Popovic, William Peter Holbrook, Thordis Kristmundsdottir, Sveinbjörn Gizurarson

Affiliations

  1. Faculty of Pharmaceutical Sciences, University of Iceland, Hofsvallagata 53, 107 Reykjavik, Iceland.
  2. Faculty of Odontology, University of Iceland, Vatnsmýrarveg 16, 101 Reykjavík, Iceland.
  3. Costco Pharmacy, Kauptúni 3, 210 Garðabær, Iceland.
  4. Pharmacy Department, College of Medicine, University of Malawi, Blantyre 3, Malawi.

PMID: 33924744 PMCID: PMC8167737 DOI: 10.3390/gels7020051

Abstract

The aim of this work was to stabilize doxycycline in mucoadhesive buccal films at room temperature (25 °C). Since doxycycline is susceptible to degradation such as oxidation and epimerization, tablets are currently the only formulation that can keep the drug fully stable at room temperature, while liquid formulations are limited to refrigerated conditions (4 °C). In this study, the aim was to make formulations containing subclinical (antibiotic) doxycycline concentration that can act as matrix metalloproteinase inhibitors (MMPI) and can be stored at temperatures such as 25 °C. Here, doxycycline was complexed with excipients using three techniques and entrapped into microparticles that were stored at 4 °C, 25 °C and 40 °C. Effect of addition of precomplexed doxycycline microparticles on films: stability mucoadhesion capacity, tensile strength, swelling index and in vitro release was studied. The complexation efficiency between drug-excipients, microparticles and films was studied using Fourier-transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC). Two of the films were found to be stable at 4 °C but the film containing microparticle composed of precomplexed doxycycline with β-cyclodextrin, MgCl

Keywords: MMPI; doxycycline; film; matrix metalloproteinase inhibitor; microparticles

References

  1. Res Pharm Sci. 2014 May-Jun;9(3):213-23 - PubMed
  2. AAPS PharmSciTech. 2013 Mar;14(1):10-8 - PubMed
  3. Curr Drug Discov Technol. 2020;17(3):376-386 - PubMed
  4. Int J Pharm Investig. 2011 Jan;1(1):42-7 - PubMed
  5. J Control Release. 2011 Apr 10;151(1):2-9 - PubMed
  6. J Young Pharm. 2011 Jul;3(3):205-10 - PubMed
  7. Turk J Pharm Sci. 2019 Sep;16(3):340-347 - PubMed
  8. J Pharm Pharm Sci. 1999 May-Aug;2(2):53-61 - PubMed
  9. Pharmaceuticals (Basel). 2019 Feb 20;12(1): - PubMed
  10. J Oral Pathol Med. 2012 Jan;41(1):61-7 - PubMed
  11. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Oct;116(4):440-6 - PubMed
  12. Oral Dis. 2004 Nov;10(6):311-8 - PubMed
  13. Saudi Pharm J. 2015 Sep;23(4):429-36 - PubMed
  14. Int J Oral Maxillofac Surg. 1993 Feb;22(1):46-9 - PubMed
  15. Drug Discov Today Technol. 2005 Spring;2(1):83-7 - PubMed
  16. J Oral Pathol Med. 2015 Jul;44(6):459-67 - PubMed
  17. AAPS PharmSciTech. 2014 Oct;15(5):1209-17 - PubMed
  18. Acta Odontol Scand. 2009;67(1):25-9 - PubMed
  19. Pharm Res. 1990 May;7(5):491-5 - PubMed
  20. Pharmazie. 2009 Mar;64(3):197-201 - PubMed
  21. J Pharm Biomed Anal. 2003 Nov 24;33(4):667-72 - PubMed
  22. Drug Deliv. 2013 Jun-Jul;20(5):224-35 - PubMed

Publication Types

Grant support